All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Topline results from the real-world study of ORG-101 for CD19+ B-ALL
Bookmark this article
On August 29, 2024, positive topline results were announced from the real-world study of ORG-101, a CD19 chimeric antigen receptor (CAR) T-cell therapy, for the treatment of CD19+ acute lymphoblastic leukemia (B-cell ALL).
Topline efficacy and safety data
- Data from 233 patients treated in the real-world setting in China were included.
- Following ORG-101 infusion, complete response rate was 82% in adult patients and 93% in pediatric patients.
- Compared with existing CAR T-cell therapies, the incidence of severe cytokine release syndrome was low; 2% in adult patients and 6% in pediatric patients.
- Orgenesis announces positive results from a real-world study of ORG-101 CAR-T therapy in patients with CD19+ acute lymphoblastic leukemia. https://www.globenewswire.com/en/news-release/2024/08/29/2937765/24226/en/Orgenesis-Announces-Positive-Results-From-a-Real-World-Study-of-ORG-101-CAR-T-Therapy-in-Patients-with-CD19-Acute-Lymphoblastic-Leukemia.html Published Aug 29, 2024. Accessed Aug 30, 2024.
More about...
Your opinion matters
13 votes - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox